Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

MRK-409

From Wikipedia, the free encyclopedia
(Redirected fromMRK-409 (MK-0343))
Abandoned drug
MRK-409[1]
Names
IUPAC name
7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
Other names
  • MK-0343
  • 1,2,4-Triazolo(4,3-b)pyridazine, 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
UNII
  • InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3
    Key: GOIFCXRIFSYPFG-UHFFFAOYSA-N
  • CN1C(=NC=N1)COC2=NN3C(=NN=C3C4=C(C=CC=C4F)F)C=C2C5CCC5
Properties
C19H17F2N7O
Molar mass397.390 g·mol−1
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

MRK-409, also known asMK-0343, is aGABAA receptorpartial agonist.[2]

It was designed to be a non-sedativeanxiolytic, however its development was halted because it produced sedation in humans.[3]

Pharmacodynamics

[edit]

Despite lacking thebenzodiazepine chemical structure, MRK-409 acts on the benzodiazepine binding site, it is therefore anonbenzodiazepine.

MRK-409 binds to theα1,α2,α3 andα5 subunits of theGABAA receptor.[4]

In rats, it produces minimal to no sedation, however it produces sedation in humans at doses above 1 mg.[3][5]

References

[edit]
  1. ^"1,2,4-Triazolo(4,3-b)pyridazine, 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-".
  2. ^"MRK-409".go.drugbank.com. Retrieved2024-02-09.
  3. ^abAtack, John R. (2010). "GABAA Receptor α2/α3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics".GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Current Topics in Behavioral Neurosciences. Vol. 2. pp. 331–360.doi:10.1007/7854_2009_30.ISBN 978-3-642-02911-0.ISSN 1866-3370.PMID 21309116.
  4. ^Atack, J. R.; Wafford, K. A.; Street, L. J.; Dawson, G. R.; Tye, S.; Van Laere, K.; Bormans, G.; Sanabria-Bohórquez, S. M.; De Lepeleire, I.; de Hoon, J. N.; Van Hecken, A.; Burns, H. D.; McKernan, R. M.; Murphy, M. G.; Hargreaves, R. J. (2011). "MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans".Journal of Psychopharmacology.25 (3):314–328.doi:10.1177/0269881109354927.ISSN 1461-7285.PMID 20147571.S2CID 5181868.
  5. ^Atack, J. R.; Hallett, D. J.; Tye, S.; Wafford, K. A.; Ryan, C.; Sanabria-Bohórquez, S. M.; Eng, Wai-Si; Gibson, R. E.; Burns, H. D.; Dawson, G. R.; Carling, R. W.; Street, L. J.; Pike, A.; De Lepeleire, I.; Van Laere, K. (2011). "Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist".Journal of Psychopharmacology.25 (3):329–344.doi:10.1177/0269881109354928.ISSN 1461-7285.PMID 20156926.S2CID 37703616.
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
Retrieved from "https://en.wikipedia.org/w/index.php?title=MRK-409&oldid=1330106749"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp